ONCY News and Press, Oncolytics Biotech Inc. From 05/08/20

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. From exciting new technology to the FDA’s ‘fast-trac...

Oncolytics Biotech (NASDAQ: ONCY ): Q1 GAAP EPS of -$0.04 beats by $0.10 . Cash and equivalents of $30.6M. Press Release More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO and CALGARY, Alberta , May 8, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shar...

SAN DIEGO and CALGARY, Alberta , May 8, 2020 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights fo...

SAN DIEGO and CALGARY, Alberta , May 4, 2020 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract for an electronic-poster ...

Oncolytics Biotech® Announces Changes to Annual General Meeting Canada NewsWire SAN DIEGO and CALGARY, Alberta, April 30, 2020 SAN DIEGO and CALGARY, Alberta , April 30, 2020 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), (the " Compan...

SAN DIEGO, California and CALGARY, Alberta , April 17, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 on...

Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer 93.3% clinical benefit rate 86% improvement over historical overall survival rates at recommended phase 2 dose Pelareorep stimulates robust antitumor adaptive ...

Gainers:  ThermoGenesis (NASDAQ: THMO ) +164% . More news on: ThermoGenesis Holdings, Inc., U.S. Gold Corp., Sientra, Inc., Stocks on the move, , Read more ...

Novavax (NASDAQ: NVAX ) +40%  on successful NanoFlu study. More news on: Novavax, Inc., ThermoGenesis Holdings, Inc., Century Casinos, Inc., Stocks on the move, , Read more ...